Nuvation Bio (NUVB) said Monday that it secured up to $250 million in non-dilutive financing deals with Sagard Healthcare Partners.
The biopharmaceutical company said the deals include a royalty interest financing, under which Sagard agreed to provide Nuvation Bio with an upfront $150 million cash payment in exchange for tiered royalties on taletrectinib's net sales in the US.
In addition, Sagard also committed to provide Nuvation Bio with a five-year, senior secured term loan of up to $100 million, according to the statement.
Shares of Nuvation Bio were up over 3% in recent trading.
Price: 2.04, Change: +0.07, Percent Change: +3.40
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。